Monday, 25 November 2019

Acromegaly Market 2019 Analysis, Opportunities and Forecast to 2023


Market Research Future adds the “Acromegaly Market Research Report- Global Forecast Till 2023” report to their unique collection. The Global Acromegaly Market is expected to grow at a CAGR of ~5.2 % during the forecast period 2017-2023.

The major driving factors for the market are increasing prevalence of acromegaly, changing lifestyle, and increasing genetic incident of genetic diseases. Moreover, increasing prevalence of hormonal diseases, for instance, endocrine diseases, and hypopituitarism, increasing government support and rapid developments in technology have fuelled the growth of the market. On the other hand, surgical costs is high, which ranges from approximately USD 2,800 to USD 9,200, however, when averaged it is less than the cost of medications. Unavailability of precise treatment and high cost of the surgery may restrain the growth of the market.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/4429

The global acromegaly market is expected to grow at a CAGR of ~5.2 % during the forecast period 2017-2023.
Acromegaly is a hormonal disorder that results from heavy secretion of growth hormones (GH) in the body. The pituitary gland in the brain, secretes GH. In acromegaly, the pituitary produces excessive amounts of GH. Usually the excess GH comes from benign, or noncancerous, tumors on the pituitary. These benign tumors are called adenomas. Acromegaly is one of the rare diseases, which most often diagnosed in the middle-aged adults and affects 5-8 people per 1 lakh people. If the diseases is not treated, it can result in serious illness and premature death. The most serious health consequences of the disease may result into high blood pressure, type 2 diabetes, increased risk of cardiovascular disease, arthritis, and others.

Key Players
·         Novartis AG (Switzerland),
·         Aegis Therapeutics LLC (US),
·         Chiasma Inc (US),
·         Crinetics Pharmaceuticals Inc (US),
·         Daewoong Pharmaceutical Co Ltd (South Korea),
·         Peptron Inc (South Korea),
·         Silence Therapeutics Plc (UK),
·         Strongbridge Biopharma plc (US),
·         Amryt Pharma plc (UK),
·         Foresee Pharmaceuticals LLC (US),
·         Glide Pharmaceutical Technologies Ltd (US),
·         Ionis Pharmaceuticals Inc (US),
·         Ipsen SA (France)
Segmentation
Acromegaly market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of treatment, the market is segmented into medications, surgery, radiation therapy, and others. The medication is further segmented into somatostatin analogues, dopamine agonists, growth hormone receptor antagonists, and others. The surgery is further segmented into endonasal transphenoidal surgery, and transphenoidal surgery.
On the basis of diagnosis, the market is segmented into medical imaging, medical laboratory investigations, others. The medical imaging is further segmented into radiography, magnetic resonance imaging (MRI), nuclear medicine, ultrasound, and others.
On the basis of type, the market is segmented into ectopic acromegaly, acromegaly due to growth hormone, and others.
Regional Analysis
Asia Pacific is the fastest growing acromegaly market. China, and India are the significant contributors to the market growth due to the presence of huge population base, increasing prevalence of acromegaly, rapidly growing healthcare sector, and increasing healthcare expenditure. Whereas, the Middle East & Africa holds the least share of the global market due to poor economic condition and limited availability of medical facilities in African region. The Middle East & African acromegaly market is majorly driven by the UAE, Saudi Arabia, and Kuwait.
The Americas commands the global market owing to increasing prevalence of acromegaly, large patient population, high healthcare spending, and strong government support for research & development. According to the Health Research Funding Organization, in America, over 3,000 new cases of acromegaly occurs per year.
Europe leads the second position of the global the market, which is followed by Asia Pacific. High healthcare expenditure, well developed healthcare sector, and increasing government support drives the growth of the market.
Browse Premium Research Report Enabled with List of Tables and Figures at @ https://www.marketresearchfuture.com/reports/acromegaly-market-4429

DATA TABLES
Table 1 Acromegaly Industry Synopsis, 2017-2023
Table 2 Global Acromegaly Market Estimates And Forecast, 2017-2023, (USD Million)
Table 3 Global Acromegaly Market By Region, 2017-2023, (USD Million)
Table 4 Global Acromegaly Market By Types, 2017-2023, (USD Million)
Table 5 Global Acromegaly Market By Diagnosis, 2017-2023, (USD Million)
Table 6 Global Acromegaly Market By Treatment, 2017-2023, (USD Million)
Table 7 Global Acromegaly Market By End Users, 2017-2023, (USD Million)
Table 8 North America Acromegaly Market By Types, 2017-2023, (USD Million)
Table 9 North America Acromegaly Market By Diagnosis, 2017-2023, (USD Million)
Table 10 North America Acromegaly Market By Treatment, 2017-2023, (USD Million)
Table 11 North America Acromegaly Market By End Users, 2017-2023, (USD Million)
Table 12 US Market By Types, 2017-2023, (USD Million)
Table 13 US Acromegaly Market By Diagnosis, 2017-2023, (USD Million)
Table 14 US Acromegaly Market By Treatment, 2017-2023, (USD Million)
FIGURES
Figure 1 Research Process
Figure 2 Segmentation For Global Acromegaly Market
Figure 3 Segmentation Market Dynamics For Global Acromegaly Market
Figure 4 Global Acromegaly Market Share, By Type 2016
Figure 5 Global Acromegaly Market Share, By Diagnosis 2016
Figure 6 Global Acromegaly Market Share, By Treatment 2016
Figure 7 Global Acromegaly Market Share, By End Users, 2016
Figure 8 Global Acromegaly Market Share, By Region, 2016
Figure 9 North America Acromegaly Market Share, By Country, 2016
Figure 10 Europe Acromegaly Market Share, By Country, 2016
Figure 11 Asia Pacific Acromegaly Market Share, By Country, 2016
Figure 12 Middle East & Africa Acromegaly Market Share, By Country, 2016
Figure 13 Global Acromegaly Market: Company Share Analysis, 2016 (%)
...Continued!
Send an Enquiry @ https://www.marketresearchfuture.com/enquiry/4429


         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:
Labels:

TMJ Disorders Market Growth and Restrain Factors Analysis By 2023

TMJ (temporomandibular joint and muscle) disorder is a medical condition which causes dysfunction and pain in the jaw joint and the muscles that control jaw movement. The medical condition is diagnosed more frequently in women than the men. According to the American Academy of Orofacial Pain, TMJ disorders may have more than one symptoms and causes. Some of the major symptoms of this disorder are aching facial pain, tenderness or pain in jaws, pain while chewing etc. TMJ disorders can occur if the joint's cartilage is damaged by arthritis or by a blow or other impact or the disk erodes or moves out of its proper alignment.
According to the recent study report published by the Market Research Future, global TMJ disorders market is booming and expected to gain prominence over the forecast period. The market is projected to demonstrate a sound growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).
The major drivers will be the increasing prevalence of TMJ disorder, rising healthcare expenditures and growing awareness for the oral health.  According to the National Institute of Dental and Craniofacial Research in 2014, the prevalence of temporomandibular joint and muscle disorder (TMJD) was in between 5% to 12%. Moreover, according to the Centers for Medicare & Medicaid Services in 2016, the U.S. healthcare expenditure was about USD 3.3 trillion, which accounted for 17.9% of the total GDP within the same year.
 However, lack of awareness and low per capita healthcare expenditure in the middle and low income countries may restrain the market growth during the forecast period.
Global TMJ Disorders Market - Competitive Analysis
Characterized by the presence of several well-established and small players, the TMJ disorders market appears to be highly competitive and fragmented. International players are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing.  The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.
Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
Pfizer Inc. is a U.S. based biopharmaceutical company and plays a significant role in the TMJ disorders market. The company’s total revenue was about USD 52,824 million in 2016. Moreover, it was estimate that the company spent 14.9% of its total revenue in research and development which made the company to improve its position in the global market and enhance its product portfolio.
In August 2016, FDA approved Pfizer's TROXYCA ER extended-release capsules CII for pain management.
In March 2017, ALLERGAN announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURE XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.
AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), Jubilant Cadista (US), Pfizer Inc. (US), and Sun Pharmaceutical Industries Ltd. (India) are some of the prominent players at the forefront of competition in the global TMJ disorders market and are profiled in MRFR Analysis.  Global TMJ Disorders Market - Regional Analysis
North America leads the market owing to well-developed healthcare infrastructure and rising per capita healthcare expenditure. Following the same trends Europe holds the second largest market share. Asia Pacific is the fastest growing region for the market due to the presence of the developed economies like India and China within the region. According to the Indian Brand Equity Foundation in 2017, Indian healthcare sector is one of the fastest growing industries which is expected to advance at a CAGR of 22.87% during 2015-20 and reach USD 280 billion by 2020.  However, Middle East and Africa holds the least market share in the global market. Presence of the stringent government policies and low per capita income in the African region restrains the market growth during the forecast period. On the other hand, Middle East leads the market of the Middle East & Africa region, due to the presence of developed economies like Kuwait and Qatar.
Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures Segmented by diagnosis (physical exam, imaging tests, and others), by treatment (medications, therapies, and others), by end user @ https://www.marketresearchfuture.com/check-discount/4090
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Hirsutism Treatment Revenue, Opportunity, Forecast and Value Chain Analysis 2019

Market Scenario:
The global hirsutism market is presumed to expand at 13.6 % CAGR during the forecast period owing to the rising expenditure on personal care, asserts Market Research Future (MRFR). Hirsutism is a condition where a woman faces unwanted and excessive male-pattern hair growth on her body. The unwanted hair growth is mainly found in areas such as back, face, stomach, and chest and is majorly caused due to hyperandrogenism which may be ovarian or adrenal. Some of the common symptoms include balding, deepening of voice, decreased breast size, acne, enlargement of the clitoris, and others.
Competitive Dashboard
The major players operating the global market are Bayer AG (Germany), Bristol-Myers Squibb Company (US), AbbVie Inc. (US), Allergan (Republic of Ireland), Sun Pharmaceutical Industries Ltd. (India), Jubilant Cadista (US), Pfizer Inc. (US), and others.
Drivers and Constraints Impacting the Market
Women are nowadays getting more conscious regarding their looks which is further influencing them to opt for hirsutism treatment. Laser therapy is one the most demanding treatments among the women driving the market. With the increasing availability of treatment and products along with the increasing awareness regarding hirsutism is propelling the market growth during the assessment period. Also, growing demand from emerging economies such as South America and Asia are likely to foster the market. Moreover, hospitals are investing in technology upgradation in order to provide effective treatment to their patients which is further expanding the market growth during the review period.
On the flip side, low per capita healthcare expenditure among the low and middle-income countries and lack of awareness regarding hirsutism are some of the major factors likely to retard the market growth in the coming years. Moreover, the cost of medical laser systems is high which makes it hard to afford for every individual, thereby hampering the market growth.
Global Hirsutism Market: Segmental Analysis
The global hirsutism market has been segmented on the basis of type, diagnosis, treatment, end-user, and region.
By mode of type, the global hirsutism market has been segmented into secondary hirsutism, idiopathic hirsutism, and others.
By mode of diagnosis, the global hirsutism market has been segmented into physical examination, blood tests, imaging tests, and others. Among these, the segment for blood-test is further sub-segmented into DHEA-sulfate test, testosterone level test, and others. The physical examination segment is sub-segmented into palpation and percussion, inspection, auscultation, and others. The imaging test is sub-segmented into CT scan, ultrasound, and others.
By mode of treatment, the global hirsutism market has been segmented into procedures, medications, and others. Among these, the medications segment is sub-segmented into anti-androgens, topical cream, oral contraceptives, and others. Procedures comprise laser therapy, electrolysis, and others.
By mode of end-users, the global hirsutism market has been segmented into hospitals and clinics, academic institutes, medical research centers, and others.
Regional Insights
Geographically, the hirsutism market span across four main regions namely, Europe, America, Asia Pacific, and the Middle East and Africa.
Among all the regions, America is estimated to hold the largest market share owing to the increasing demand for treatment and technological advancements in this region. North America is considered to be the dominant region in America. The U.S. generates the highest revenue in this region.
Asia Pacific is considered to be the fastest growing region owing to increasing expenditure on healthcare, growing awareness regarding hirsutism, and availability of affordable healthcare facilities in this region.
Europe is considered to be the second largest market owing to the presence of countries such as France, Germany, and the U.K. On the other hand, the Middle East and Africa showcases the least market share and is anticipated to expand at a slower rate than the average growth rate.
Industry News
A change in the law in Western Australia has drastically reduced the price of laser hair removal. SILK Laser Clinics, which once sold a 67 % stake to the Advent Partners in a deal valuing it between $50 million and $100 million, has opened its first two clinics in WA.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures Segmented By Type (Idiopathic Hirsutism, Secondary Hirsutism, and others), By Diagnosis (Blood Tests, Imaging Tests, Physical Examination), By Treatment (Medications, Procedures, and others), By End User @ https://www.marketresearchfuture.com/reports/hirsutism-treatment-market-3857
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Africa Malaria Diagnosis & Treatment to show steady growth, 2019

According to World Health Organization (WHO), the global incidence of malaria between 2010 and 2015, fell by 21% and the malaria mortality fell by 29%. However the African region carries a disproportionately high share of the global malaria burden and accounted for 90% of malaria cases and 92% of malaria deaths worldwide and sub-Saharan Africa accounted for 76% of malaria cases and 75% deaths globally.
Africa malaria diagnosis market to reach around $ 2418.92 million from $ 550 million in 2017, by the end of the forecast period at a CAGR of ~ 28.0 %. While the malaria treatment market will grow by a CAGR of 8.1% to reach around $ 7180.7 million from $ 4500.0 million in 2016.
The growth of government programs against malaria and the support given by international bodies such as WHO is also a market driver. The market barriers include high cost of imported malaria diagnostic kits, low penetration of healthcare in Africa, low per capita income, low number of healthcare professionals in Africa etc. The political causes include massive corruption, low political power of citizens especially in nondemocratic nations, civil war in regions such as Malawi etc.
Malaria is an infectious disease caused by parasitic protozoa of the Plasmodium type. The symptoms include fever, fatigue, vomiting, and severe headaches and may lead to seizures, coma, or even death if untreated. Malaria is primarily a disease of the tropical and subtropical regions. The carrier of malaria is the female anopheles mosquito and hence there is a seasonal variation in the cases of malaria. Most cases of malaria are caused by P. falciparum because other types of plasmodium such as P. vivax, P. ovale, and P. malariae generally cause a milder form of malaria.
Segmentation:
Africa Malaria Diagnosis & Treatment Market has been segmented on the basis of technique which comprises rapid diagnostic tests (RDT’S), molecular diagnostics and microscopy. On the basis of malarial parasite; market is segmented into plasmodium falciparum, plasmodium vivax, plasmodium malariae and plasmodium ovale.
Key Players
  • Alere Inc.
  • Access Bio Inc.
  • Premier Medical Corporation
  • Beckman Coulter/Danaher
  • bioMerieux
  • Novartis Diagnostics
  • Siemens Healthcare
  • Bio-Rad Laboratories, Cipla Inc.
  • Ipca Laboratories Ltd.
  • Uni-Med India
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sanofi
Regional Analysis
The healthcare sector of Africa is divided between private and state. The public healthcare expenditure accounts for approximately 48 % of total health expenditure in 2014 with variation in different countries. Local manufacturing represents a poor outlook which is limited to consumables and ordinary articles and there are a handful of high tech devices manufacturers. Africa is extremely dependent on imports for medical devices and imports account for approximately 90 % of total market for medical devices and Chinese medical device suppliers dominate the scenario. Among the regions of Africa, South Africa and Egypt account for 40 % of market. Other important nations are Nigeria, Morocco and Algeria. Collaboration with large global companies and technical transfer will remain the key strategy for developing the regional African market as can be seen by the example of China.
Browse Complete 60 Pages Premium Research Report Enabled with Respective Tables and Figures Segmented by Diagnosis (Rapid Diagnostic Tests (RDT’s), Molecular diagnostics, Microscopy), by Malarial Parasite (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malariae and Plasmodium Ovale) @ https://www.marketresearchfuture.com/reports/malaria-diagnosis-treatment-market-2952
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Nasal Drug Delivery to Observe Significant Growth by 2019

The global nasal drug delivery market is expected to grow significantly over the forecast period. The global market was valued at approximately USD 52,998.5 million in 2018 and is projected to grow with 6.6% CAGR over the forecast period.
Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.
Factors such as the painless drug administration, development of new technological nasal drug delivery devices, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists. 
However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the market growth.
Segmentation
The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.
Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.
Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.
Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.
Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.
Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
The global market, by end user, has been divided into home care settings and hospitals & clinics.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region. 
Key Players
GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.
Regional Market Summary
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.
Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.
Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.
Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.
Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.
The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.
Browse Premium Research Report Enabled with Respective Tables and Figures Segmented by Drug Type (Anesthetics, Antibiotics), Dosage Form (Drops, Sprays), Basis of System (Unit Dose, Multi-Dose), Delivery Technologies (Spray, Nebulizers), Therapeutic Applications (Rhinitis, Asthma) End User (Home Care Settings) @ https://www.marketresearchfuture.com/reports/nasal-drug-delivery-market-2696
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com`
Posted by at No comments:
Labels:

Stroke Disorder and Treatment Growth and Restrain Factors Analysis By 2023

The Global Stroke Disorder and Treatment Market is presumed to demonstrate a healthy CAGR during the forecast period (2016-2022) owing to the rising high blood pressure patients, asserts Market Research Future (MRFR).
Heart problems and brain problems are considered among most dangerous medical problems, and their treatments are considered to be most expensive. Heart strokes and brain strokes can strike any moment and can be fatal. Hence, the market offering treatment for it is always lucrative. Globally it is increasing rapidly. The major factor that drives the growth of this market is the increasing high blood pressure patients. Due to increasing alcoholism and patients with diabetes, cardiovascular diseases are increasing the growth of this disorder and the market offering its treatment.
Stroke is referred to as the condition which occurs when clot is formed in the artery and oxygen supply is cut off. Brain cells thus get deprived of oxygen and start to die. Heart and brain strokes can strike any moment and can be fatal. Stroke is considered as one of the leading causes of death across the world with higher prevalence in the geriatric population.
Competitive Dashboard
  • AstraZeneca (U.K),
  • Bayer Pharma AG (Germany),
  • Novartis AG (Switzerland),
  • Daiichi Sankyo (Japan),
  • Pfizer (U.S).
Drivers and Constraints Impacting the Market
With increasing consumption of alcohol and diabetic patients, the global stroke disorder and treatment market is likely to flourish. Also, the increasing prevalence of cardiovascular diseases is highly influencing the market across the globe. Brain problems and heart problems are considered as the most dangerous medical issues across the world with expensive medication and treatments. Thus, the market offering treatment for it is lucrative. The market is further accelerated by the huge patient pool along with rising geriatric population across the globe. Moreover, atrial fibrillation, hypertension, and coronary heart diseases are contributing to the growth of the market.
On the flip side, high cost of treatment adversely affects the growth of the market. Moreover, the lack of transparent reimbursement scenario is also likely to dampen the stroke disorder and treatment market during the assessment period.
Global Stroke Disorder and Treatment Market: Segmental Analysis
The global stroke disorder and treatment market has been segmented on the basis of type, medicine, treatment, and region.
By mode of type, the global stroke disorder and treatment market has been segmented into ischemic stroke and hemorrhagic strokes. Among these, the weakened blood vessel leakage is referred to as hemorrhagic stroke. Ischemic stroke generally occurs due to an obstruction within a blood vessel which supplies blood to the brain.
By mode of medicine, the global stroke disorder and treatment market has been segmented into anticoagulants/antiplatelet, anti-hypertensive.
By mode of treatment, the global stroke disorder and treatment market has been segmented into tissue plasminogen activator (TPA), carotid endarterectomy, surgical treatment, endovascular procedures, and others. TPA is referred to as an enzyme involved in the breakdown of blood clots and dissolves them. It is a less invasive procedure and is used for treating problems affecting the blood vessels like aneurysm.
Regional Insights
Geographically, the stroke disorder and treatment market span across regions namely, Europe, North America, Asia Pacific, and Rest-of-the-World.
Among these, the North America region is presumed to dominate the stroke diagnostics and therapeutics market and is likely to maintain its dominance. The growth is attributed to the rising awareness among the population regarding the symptoms of stroke followed by the several harmful effects associated with high glucose level in blood. With technological advancements and high-end research, and rising public interest, the demand for stroke disorder and treatment is likely to trigger in the coming years. Moreover, encouraging healthcare infrastructure and higher healthcare expenditure are some of the major factors contributing to the growth of the stroke disorder and treatment market.
European holds the second-largest position with high diabetic population. Moreover, the growing percentage of diabetes mellitus population is directly proportionate to the associated risk of stroke in individuals, thereby contributing to the market growth during the assessment period. Additionally, technological advancements and healthcare research are further influencing the market growth.
Industry Updates
CERENOVUS business has recently launched the single largest global registry, the EXCELLENT Registry, in order to collect and analyze stroke-inducing blood clots removed from the brain with its EMBOTRAP II Revascularization Device. The EXCELLENT Registry is likely to enroll up to 1000 ischemic stroke patients in as many as 50 clinical sites in Europe and the United States.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures Segmented by types (ischemic stroke, hemorrhagic strokes) by medicine (an-ticoagulants, anti-hypertensive) by treatment (tissue plasminogen activator (TPA), endovascular procedures) @ https://www.marketresearchfuture.com/reports/stroke-disorder-treatment-market-1651

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Friday, 22 November 2019

Amyotrophic Lateral Sclerosis Market Profound Impact on the Market by Growing Healthcare Sector during the Forecast Period 2019-2023

The Global ALS market valuation is expected to surpass USD 841.6 million by 2023, growing at approximately 7.89 % CAGR over the forecast period (2019-2023). In 2017, the market had a valuation of USD 526 million. Market Research Future presents report by By Type (Familial ALS), by Treatment (Medication, Physical Therapy, Speech Therapy), by Diagnosis (Laboratory Tests, Imaging Tests), End-User (Hospitals, Specialty Centers) and Global forecast till 2023
ALS or Amyotrophic Lateral Sclerosis is a neurological ailment which affects the nerve cells in the spinal cord and the brain that controls the voluntary muscles’ activities. Some of the common symptoms of ALS include cramps, muscle weakness, respiratory problems, and fasciculation. This is a progressive neurological disease where gradually patients become dependent on physicians and caregivers increasingly. Often ALS results in respiratory failure as the patient loses the ability of controlling the muscles both in the diaphragm and the chest. Ultimately, it turns fatal.
Additional factors such as the inclination towards the sedentary lifestyle are driving the market growth and increasing the risk of developing ALS. Besides, the increasing geriatric population substantiates market growth, creating a demand for symptomatic and targeted treatment options.
But the high cost of the treatment of ALS may hinder the market growth over the forecast period.
Key Players                                                                                                         
  • Sun Pharmaceutical (India),
  • Mitsubishi Tanabe Pharma America (U.S.),
  • Biogen (U.S.),
  • Sanofi (France),
  • Mylan N.V. (U.S.),
  • Covis Pharma (Switzerland),
  • Ionis Pharmaceutical (U.S.),
  • ITF Pharma (U.S.),
  • Ascend Pharmaceuticals LLC (U.S.),
  • Apotex Inc. (Canada).
Feb 2019- Leading technology transfer company, BGN Technologies has lately disclosed about a new AI (artificial intelligence) platform to monitor and predict the development of neurodegenerative diseases in order to identify markers both for improved drug development and personalized patient care. This technology will focus on ALS at an initial stage and later on will be adapted to other neurodegenerative diseases namely Alzheimer’s and Parkinson’s. The latest technology will predict disease progression more accurately, a key component for clinical trials along with better identifying the interrelationships amid demographics and many other measurable factors that are identified through patient functionality and physical examinations. It will allow researchers in creating a system which insurers, HMOs, pharmaceutical companies, caregivers, physicians, and patients can use on mobile applications and desktop for monitoring and predicting ALS progression.
Segments                                                                                                                                            
The Global amyotrophic lateral sclerosis market has been segmented on the basis of type, treatment, and end-user.
By type, the market is segmented into sporadic and familial ALS. The sporadic ALS, also abbreviated as SALS, was the largest segment in 2017 and can dominate the market over the forecast period.
By treatment, the amyotrophic lateral sclerosis market has been segmented into medication, physical therapy, respiratory therapy, speech therapy, and others. Out of these, medication had the largest market in 2017.
By end-user, the ALS market has been segmented into hospitals, specialty centers, research & academic institutes, and others. Among these, the subsegment Hospital accounts for the largest segment.
Regional Analysis
By Regions, the global amyotrophic lateral sclerosis market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is estimated to dominate the global ALS market owing to the increasing pool of awareness and the rising prevalence of hypertension. ALS remains a significant public health challenge in the US. Therefore, governments and private non-profit organizations are developing specific guidelines for the management and treatment of ALS. Public and private organizations are involved in strategic partnerships and collaborations in search for a better outcome in the research of amyotrophic lateral sclerosis treatment in the region.
The amyotrophic lateral sclerosis market in the European region stands at the second position in terms of the market size mainly due to the well-established healthcare sector. Several companies and research institutes are also establishing advanced facilities to research ALS.
Moreover, in recent years, there has been an increase in the adoption of sedentary lifestyles among people. Research shows that an increase in physical activities such as exercise helps in reducing the pain and thwarting some of the symptoms such as loss of motion in patients who have ALS.
Thus, the inclination towards the sedentary lifestyle increases the risk of developing ALS among the elderly population, thus creating a demand for symptomatic and targeted treatment options. The development of novel therapeutic approaches and advanced treatment options are likely to push the growth of the amyotrophic lateral sclerosis market during the forecast period.
Whereas, the ALS market in the Asia Pacific region is expected to grow rapidly due to the increasing prevalence of the disease and rapidly developing healthcare infrastructure. The increasing economy in the region is playing a vital role in the growth of the market. Furthermore, the increase in the setups of research and development centers also fuels the growth of the ALS market in the region.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures Segmented by Type (Familial ALS), by Treatment (Medication, Physical Therapy, Speech Therapy), by Diagnosis (Laboratory Tests, Imaging Tests), End-User (Hospitals, Specialty Centers) @ https://www.marketresearchfuture.com/reports/amyotrophic-lateral-sclerosis-market-5822  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)